Hannah Levy, Scientific Intelligence Analyst and Global Moderator at MedNews Week, shared a post on LinkedIn:
“In oncology, some of the most important advances are not necessarily new treatments— they are new ways of achieving similar or better outcomes with less burden on patients.
A recent MedNews Week | OncoDaily lecture by Dr. Paolo Strati explored the evolving role of AR² therapy in indolent B-cell lymphomas and the growing potential of chemotherapy-free treatment approaches.
A few themes stood out to me:
- Targeted therapies continue to expand frontline treatment options beyond traditional chemotherapy-based regimens
- Combining immunotherapy with targeted agents may offer an opportunity to improve outcomes while maintaining tolerability
- Treatment decisions increasingly involve balancing disease control, toxicity, quality of life, and long-term management considerations
What I found particularly interesting was the broader shift in thinking: success is no longer measured solely by response rates, but also by how effectively therapies can be integrated into patients’ lives over time.”
More posts featuring Hannah Levy.
